10-K: BioXcel Therapeutics Navigates Financial Challenges While Advancing Neuroscience Pipeline

Sentiment:

Annual Report 28 March 2025 4:05 PM

📋All filings for Bioxcel Therapeutics, INC

BioXcel Therapeutics faces financial headwinds but remains focused on clinical development of BXCL501 and exploring strategic options.

Delay expectedDevelopments relating to the TRANQUILITY II Phase 3 trial may impact the timing of development plans for BXCL501.

Capital raiseThe Fifth Amendment to our Credit Agreement included a new capital raising covenant requiring that the Company receive (A) after the effective date of the Fifth Amendment and on or prior to November 27, 2024, at least $7.0 million in gross cash proceeds from the issuance of the Companys common stock, warrants and/or pre-funded warrants (Raise 1), (B) after the effective date of the Fifth Amendment and on or before March 15, 2025 (provided that the Company was required to use its commercially reasonable efforts to satisfy the requirement by February 15, 2025), at least $18.0 million in net cash proceeds (including the proceeds of Raise 1) from (i) the issuance of the Companys common stock, warrants and/or pre-funded warrants, (ii) non-refundable cash consideration from partnering transactions entered into after the effective date of the Fifth Amendment (so long as such partnering transactions would not require the Company or any of its subsidiaries to make any cash investments in connection with the partnering transactions and no such cash investments are made), (iii) the issuance of the Companys subordinated debt (subject to terms set forth in the Fifth Amendment), and/or (iv) asset sales permitted pursuant to the Credit Agreement or consented to by the Lenders (such capital raise, Raise 2), and (C) after the effective date of the Fifth Amendment and on or prior to the earlier of (x) August 15, 2025 and (y) the date that is 30 days after the final data readout of the SERENITY At-Home Phase 3 trial, at least $29.0 million in net cash proceeds (Raise 3) (including the proceeds from Raise 1 and Raise 2) from the same permitted capital raising activities listed in the preceding clause (B).

Worse than expectedThe company has identified conditions and events that raise substantial doubt regarding its ability to continue as a going concern.The company received a Nasdaq delisting notice due to its market value falling below $35 million, and a hearing is pending.

Summary

BioXcel Therapeutics (BTI) is a biopharmaceutical company focused on neuroscience and immuno-oncology, utilizing AI to develop new medicines.
The company's lead neuroscience candidate is BXCL501, being developed for agitation associated with psychiatric and neurological disorders.
IGALMI, a sublingual film for acute agitation associated with schizophrenia or bipolar disorder, is BTI's only approved product.
BTI is conducting a SERENITY At-Home trial to evaluate BXCL501 for at-home use in treating agitation associated with bipolar disorders or schizophrenia, with topline data expected in the second half of 2025.
TRANQUILITY In-Care Phase 3 trial is planned to evaluate BXCL501 for agitation associated with Alzheimer's dementia.
BTI received a Nasdaq delisting notice due to its market value falling below $35 million, and a hearing is pending.
The company implemented clinical prioritization, including workforce reductions, to extend its cash runway and focus on BXCL501's clinical development.
Net revenues from IGALMI product sales for 2024 were $2.3 million, compared to $1.4 million in 2023.
BTI is seeking potential commercial partners for IGALMI.
The company has significant debt and has identified conditions that raise substantial doubt about its ability to continue as a going concern.
BTI is also involved in government-supported investigator-sponsored trial programs for BXCL501 in opioid use disorder, alcohol use disorder with comorbid PTSD, and acute stress disorder.
OnkosXcel, BTI's wholly-owned subsidiary, is developing BXCL701, an oral innate immune activator, for aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
The FDA has granted BXCL701 Fast Track designation for metastatic SCNC with progression on chemotherapy and no evidence of microsatellite instability.
BTI relies on third parties for manufacturing and clinical trials.
The company faces intense competition in the pharmaceutical and biotechnology industries.
As of March 21, 2025, BioXcel LLC holds an ownership interest of approximately 8.8% in BTI.
The company's cash and cash equivalents of $29.8 million as of December 31, 2024, together with approximately $14.0 million gross proceeds received from the registered direct offering in March 2025, will allow the Company to fund its operations and meet its liquidity requirements into the third quarter of 2025.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in the clinical pipeline and revenue growth for IGALMI, the financial challenges, Nasdaq delisting notice, and dependence on future funding create significant uncertainty and risk.

Positives

IGALMI net revenues increased to $2.3 million in 2024 from $1.4 million in 2023.
SERENITY At-Home trial is underway to evaluate BXCL501 for at-home treatment of agitation, with topline data expected in the second half of 2025.
TRANQUILITY In-Care Phase 3 trial protocol submitted to the FDA to evaluate BXCL501 for agitation associated with Alzheimers dementia.
BXCL701 received FDA Fast Track designation for metastatic SCNC with progression on chemotherapy and no evidence of microsatellite instability.
A U.S. Department of Defense grant was awarded to study BXCL501 for treating Acute Stress Disorder (ASD).

Negatives

BTI received a Nasdaq delisting notice and a hearing is pending.
Clinical prioritization and workforce reductions were implemented to extend cash runway.
BTI has significant debt and has identified conditions that raise substantial doubt about its ability to continue as a going concern.

Risks

The company's limited operating history and lack of substantial product revenues make it difficult to evaluate its future viability.
The company has incurred significant operating losses and anticipates continuing to do so.
The company needs substantial additional funding, and failure to raise capital could force it to delay, reduce, or eliminate product development programs.
The company faces the risk of Nasdaq delisting, which could limit investors' ability to make transactions in its securities.
The company has significant indebtedness that could impair its liquidity and restrict its ability to do business.
The company's strategic reprioritization and workforce reductions may not achieve the intended outcome.
Developments relating to the TRANQUILITY II Phase 3 trial may impact the timing of development plans for BXCL501.
The company is dependent on the success of IGALMI and the development of BXCL501, BXCL502, and BXCL701.
The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, expensive, and unpredictable.
Clinical trials are expensive, difficult to design and conduct, and involve an uncertain outcome.
The company depends on enrollment of patients in its clinical trials.
The company's estimated number of agitation episodes and total addressable market are subject to inherent challenges and uncertainties.
The discovery and development of product candidates based on EvolverAI is novel and unproven.
Regulators may limit the company's ability to develop or implement its proprietary AI algorithms.
The company faces extensive and ongoing regulatory requirements and obligations for IGALMI and any product candidates for which it obtains approval.
The company's products and product candidates may not be accepted by physicians or the medical community, and there may be insufficient insurance coverage and reimbursement.
The company may be found in violation of federal, state, or foreign health care fraud and abuse laws.
The company continues to depend on BioXcel LLC to provide certain services for its business.
The company is substantially dependent on third parties for the manufacture of its clinical supplies of product candidates and commercial supplies of IGALMI.
The company relies on third parties to conduct its preclinical and clinical trials.
Data breaches or cyber-attacks could disrupt the company's business, operations, and information technology systems.
The company is and may in the future be subject to legal proceedings, claims, and investigations.
Unfavorable global political or economic events and conditions could adversely affect the company's business.
The company faces risks associated with the increased scrutiny relating to environmental, social, and governance matters.
It is difficult and costly to protect the company's proprietary rights, and it may not be able to ensure their protection.

Future Outlook

The company anticipates continuing to develop and conduct clinical trials with respect to its current and any future product candidates; seek to identify and develop additional product candidates; acquire or in-license other product candidates or technologies; seek regulatory approvals for its product candidates that successfully complete clinical trials, if any; establish sales, marketing, distribution and other commercial infrastructure to support the commercialization of products for which it may obtain marketing approval; require the manufacture of larger quantities of product candidates for clinical development and, potentially, commercialization; maintain, expand and protect its intellectual property portfolio; hire and retain limited additional personnel, such as clinical, quality control and scientific personnel; add operational, financial and management information systems and personnel, including personnel to support its product development and help it comply with its obligations as a public company; and add equipment and physical infrastructure to support its research and development programs.

Management Comments

Management believes that the Company's cash and cash equivalents of $29.8 million as of December 31, 2024, together with approximately $14.0 million gross proceeds received from the registered direct offering in March 2025, will allow the Company to fund its operations and meet its liquidity requirements into the third quarter of 2025.

Industry Context

The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. The neuroscience and rare disease segments of the industry are highly competitive.

Comparison to Industry Standards

The successful business models of biotech companies like Axsome Therapeutics, Inc. and Karuna Therapeutics, Inc. (acquired by Bristol Myers Squibb) are based on the re-innovation and combination of existing clinical candidates or marketed drugs to provide novel solutions for patients.
Drugs used for the acute treatment of agitation related to schizophrenia and bipolar disorder are antipsychotics frequently administered via IM injection that typically requires patient restraint.
These include IM aripiprazole, olanzapine, ziprasidone, and haloperidol.
Oral products include the sublingually administered atypical antipsychotic Asenapine, as well as benzodiazepines, lorazepam, and midazolam.
The typical antipsychotic Adasuve (loxapine) from Alexza is delivered via inhalation.

Legal Proceedings

The Company is cooperating with a formal investigation of the Company and certain of its officers and directors by the SEC, relating to the Companys public disclosures, including about product sales and the receipt of a Form 483 by an investigator at one of the Companys clinical trial sites in the TRANQUILITY II study, and trading in the securities of the Company.

Related Party Transactions

As of March 21, 2025, BioXcel LLC holds an ownership interest of approximately 8.8% in the Company.
The Company continues to depend on BioXcel LLC to provide it with certain services for its business.
The management of and beneficial ownership in BioXcel LLC may create, or may create the appearance of, conflicts of interest.

Stakeholder Impact

Shareholders face potential dilution from future stock issuances and the risk of stock price decline due to various factors.
Employees have been affected by workforce reductions and may experience decreased morale.
Customers (hospitals and healthcare providers) may be impacted by changes in commercial strategy for IGALMI.
Suppliers and creditors may be affected by the company's financial challenges and potential restructuring.
Patients may benefit from the continued development of new treatments for agitation and other conditions.

Next Steps

Continue the SERENITY At-Home trial and expect topline data results in the second half of 2025.
Generate additional Phase 3 efficacy and safety data in care facilities for the TRANQUILITY program.
Discuss the details of the requirement for long-term safety data with the FDA.
Seek FDA feedback on potential registrational paths for BXCL501 in opioid use disorder.
Continue patient screening and enrollment in the Alcohol Use Disorder with Comorbid Post-traumatic Stress Disorder Program.
Commence patient screening and enrollment in the Acute Stress Disorder (ASD) Program in the first half of 2025.
Continue to seek potential commercial partners for IGALMI.
Continue to monitor performance with respect to Nasdaq listing standards and consider available options to resolve any deficiency and maintain compliance.

Key Dates

Date	Description
March 29, 2017	BioXcel Therapeutics, Inc. was incorporated as a Delaware corporation.
June 30, 2017	Effective date of the Separation and Shared Services Agreement with BioXcel LLC.
April 6, 2022	FDA approved IGALMI sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
April 19, 2022	Formation of wholly owned subsidiary, OnkosXcel.
July 6, 2022	IGALMI commercially available in doses of 120 and 180 micrograms.
September 16, 2024	Company received a letter from Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2).
September 17, 2024	Company approved a plan for an additional reduction in its workforce.
September 20, 2024	Company received a letter from Nasdaq Staff notifying it that the Companys market value of listed securities closed below the minimum $35 million requirement.
February 6, 2025	Company announced it would effect a 1-for-16 reverse stock split of its common stock.
February 7, 2025	Reverse stock split became effective.
February 10, 2025	Company's common stock began trading on a split-adjusted basis.
February 26, 2025	Company met the requirement to maintain a minimum closing bid price of $1.00 per share for at least 12 consecutive trading days.
March 3, 2025	FDA concluded that the inspection of a single site in its TRANQUILITY II Phase 3 trial was closed.
March 4, 2025	Company entered into the Sixth Amendment to its Credit Agreement.
March 20, 2025	Company received another letter from the Staff stating that its securities would be delisted from Nasdaq unless the Company appealed the Staffs delisting determination.
March 26, 2025	There were 5,486,038 shares of our common stock outstanding.
March 27, 2025	24 clinical trial sites had been opened and 127 patients have been enrolled in the SERENITY At-Home trial.

Keywords

BXCL501, IGALMI, agitation, clinical trials, BioXcel Therapeutics, BXCL701, FDA, neuroscience, immuno-oncology, AI, financial results, risk factors

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.